Skip to content

Mechanistic and Application Research of S100A12 in Sepsis-Associated Acute Kidney Injury

Mechanistic and Application Research of S100A12 in Sepsis-Associated Acute Kidney Injury

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400094790
Enrollment
Unknown
Registered
2024-12-27
Start date
2023-09-08
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis associated-acute kidney injury

Interventions

Acute kidney injury :None
Non acute kidney injury:None

Sponsors

Jining No.1 People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion/exclusion criteria; Subjects: Adult patients diagnosed with sepsis within 24 hours of admission. Diagnostic criteria: (1) The diagnostic criteria for sepsis are SEPSIS 3.0 criteria, that is, a rapid increase in SOFA score after infection >=2 as the clinical judgment criterion for organ dysfunction in sepsis. (2) The diagnostic criteria for acute kidney injury follow the latest KDIGO guidelines, including the diagnosis of AKI in one of the following conditions: 1) an increase in Scr of more than 26.5 micromol/L (0.3 mg/dl) within 48 hours; 2) SCR elevation greater than 1.5 times baseline – confirmed or presumed to occur within 7 days; 3) Urine output < 0.5ml/(kg·h) for more than 6 hours. (3) Acute kidney injury following the onset of sepsis in patients is defined as SA-AKI.

Exclusion criteria

Exclusion criteria: 1.Presence of other underlying kidney diseases, such as chronic renal insufficiency, adrenocortical insufficiency, etc.; 2.Presence of patients with acute cardiovascular and cerebrovascular diseases that lead to death within 24 hours; 3.Patients who have previously undergone kidney transplantation or kidney surgery; 4.Pregnant or lactating women; 5.Patients with intellectual or psychological disabilities who are not suitable for participating in the study.

Design outcomes

Primary

MeasureTime frame
Concentration of S100A12 in plasma;S100A12 transcription level differences;

Countries

China

Contacts

Public ContactJikui Shi

Jining No.1 People's Hospital

sjkjnrmyy@126.com+86 159 6572 1736

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026